



PRESS RELEASE

**Adocia to hold an ordinary shareholders' meeting
on November 9, 2018 in Lyon**

Lyon, October 5th, 2018 – 6pm CET- Adocia (Euronext Paris: FR0011184241 - ADOC) will hold an ordinary shareholders' meeting ("AGO") on November 9, 2018, at 10:30 am at its registered office, 115 avenue Lacassagne, in Lyon (69003).

The notice of this shareholders' meeting serving as convening notice published today, in the French *Bulletin des Annonces Légales Obligatoires* ("BALO") includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting.

This notice is also available on the company's website:

<http://www.adocia.fr/WP/investors-welcome/shareholders-meeting>.

All documentation regarding this AGO will be made available to shareholders in accordance with existing regulations and will be available on the company's website from October 19, 2018

Precisions regarding the AGO:

Only shareholders having registered their shares at least two business days prior to the date of the AGO, by midnight Paris time, will be able to participate in the AGO.

Shareholders holding bearer shares ("actions au porteur") will need to obtain a certificate of shareholding ("attestation de participation") from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post.

The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGO in person.

Each shareholder may submit a question in writing to the Board of Directors, this question being treated during the shareholders meeting. Questions should be sent by registered mail with return receipt to the following address: ADOCIA, 115 avenue Lacassagne - 69003 Lyon or electronic communication to the following address: ag2018@adocia.com.

The written question must be sent no later than the fourth business day preceding the date of the general meeting and must imperatively be accompanied by a certificate of attendance in order to be treated.

Shareholders may obtain the legal documentation in preparation of the AGO as described in the article R.225-83 of the French Commercial Code by sending a request:

- By regular mail to: Adocia - Service Relations Investisseurs – 115 avenue Lacassagne, 69003 Lyon, or
- By e-mail to: ag2018@adocia.com.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. In the diabetes field, Adocia's portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring six clinical-stage products. Additionally, Adocia recently expanded its portfolio to include the development of treatments of obesity and short bowel syndrome.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. Adocia's clinical pipeline includes five novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone® Combo), a rapid-acting formulation of human insulin (HinsBet® U100), and a prandial combination of human insulin with amylin analog pramlintide (BioChaperone® Pramlintide Insulin). It also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia. Adocia preclinical pipeline includes combinations of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine GLP-1) for the treatment of diabetes, a ready-to-use combination of glucagon and a GLP-1 receptor agonist BioChaperone® Glucagon GLP1) for the treatment of obesity and a ready-to-use aqueous formulation of teduglutide (BioChaperone® Teduglutide) for the treatment of short bowel syndrome.

Adocia and Chinese insulin leader Tonghua Dongbao recently entered into a strategic alliance. In April 2018, Adocia granted Tonghua Dongbao licenses to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle-Eastern territories. The licensing included 50 million dollars upfront and up to 85 million dollars development milestones, plus double-digit royalties on sales. In June 2018, Tonghua Dongbao agreed to manufacture and supply active pharmaceutical ingredients insulin lispro and insulin glargine to Adocia globally, excluding China, to support Adocia's portfolio development in these territories.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com



For more information please contact:

<p>Adocia G�rard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph. : +33 4 72 610 610</p>	<p>Adocia Press Relations Europe MC Services AG Raimund Gabriel adocia@mc-services.eu Ph. : +49 89 210 228 0</p>	<p>Adocia Investor Relations USA The Ruth Group Tram Bui tbui@theruthgroup.com Ph.: +1 646 536 7035</p>
--	---	--